Price action shows XP trading near multi-month lows around $15-16.50 after a decline from the $20+ range in early 2026, creating a potential entry point at $16.16 with support holding in recent weeks. Fundamentals appear solid with a low P/E of 8.8, strong ROE of 22.9%, and healthy net margins of 28.1%, suggesting undervaluation for a financial services firm despite the weak current ratio of 0.19. Key risks over 2-12 weeks include elevated beta-driven volatility from interest rate shifts or Brazilian macro events that could pressure the stock further before any rebound. Overall this supports a BUY verdict with estimated 15-25% upside potential to the $18.50-$20 zone if momentum returns within the swing horizon.

XP is currently trading near a significant support level around $15.50-$16.00, which has historically acted as a floor for the stock over the past year. The company maintains strong fundamental health with a low P/E ratio of 8.8 and a robust net margin of 28.1%, suggesting the stock is undervalued relative to its earnings power. While the current ratio is low, the high ROE of 22.9% indicates efficient capital management that should support a rebound as market sentiment stabilizes. I anticipate a recovery toward the $18.50-$19.00 range within the 2-12 week horizon, offering an estimated upside potential of approximately 15-20% from the current entry point.

XP is currently at $16.16, which sits near the lower end of its recent trading range but shows no clear bullish setup for a 2-12 week swing trade. Price action over the past 6 months reveals a volatile, range-bound pattern with resistance around $20-21 and support near $15-16; the stock has failed to break above $22 despite multiple attempts and is now consolidating at support, lacking the momentum confirmation needed for a reliable swing entry. While fundamentals appear solid (low P/E of 8.8, strong ROE of 22.9%, 28% net margin), the critical red flag is the extremely weak current ratio of 0.19, indicating severe liquidity constraints that could trigger forced selling or limit upside catalysts in the near term. The news items provided (Bouygues/Orange/Free consortium MoU and Xeris Biopharma earnings) appear unrelated to XP and provide no clear catalyst; without fresh positive news or technical breakout confirmation, the risk/reward is unfavorable—potential upside to $19-20 (12-24% gain) is offset by downside risk to $14.50 (10% loss) and the liquidity concerns that could prevent a clean exit. Better entry points would emerge on a confirmed breakout above $20.50 with volume, or a deeper dip to $14.50 with positive catalyst news.

1) Price action: XP is not in an obvious entry point right now. It sits around 16.1 with a downtrend from earlier highs near 21-22 in recent months, and it would need a clear breakout above roughly 17.5-18 with solid volume to confirm momentum. 2) Fundamental health: The stock shows strong profitability (ROE ~23%, net margin ~28%, P/E ~8.8, EPS ~$9.71) and decent revenue growth, suggesting it is attractively valued on a fundamentals basis. However, the liquidity metric is a red flag: current ratio of 0.19 implies potential short-term liquidity stress, which is atypical for a swing trade and can provoke volatility. 3) Key risks on 2-12 weeks: continued macro-pressure or sector rotation could push the stock lower; liquidity risk could amplify drawdowns; M&A-related news (such as the Bouygues/Orange/Free-iliad SFR development) could create add-on volatility unrelated to XP’s fundamentals; the chart also shows risk of a deeper pullback if 16 support fails. 4) Final verdict with upside potential: Given the lack of a confirmed bullish setup, I’d avoid entering now. If the stock does break and hold above 18 with volume, the upside could target the 20-22 zone (roughly 25-38% from 16), but until that momentum is evident the risk/reward is not favorable for a near-term swing entry at 16.16.